Article
Open Access Article

Restoring Patency to Central Venous Access Devices

Cynthia Cummings-Winfield

Tayreez Mushani-Kanji

central venous access device, evidence-based practice
CJON 2008, 12(6), 925-934. DOI: 10.1188/08.CJON.925-934

In September 2006, the Oncology Nursing Advisory Board met to discuss the current management of central venous access device (CVAD) occlusions for patients receiving cancer treatment in centers across Canada. The board found inconsistency in practice across the country and advocated for the development of evidence-based, standardized guidelines for the use of thrombolytic agents to clear thrombotic occlusions. PubMed was searched for articles related to catheter occlusion, catheter patency, and catheter complications published from 1997-2007. The board compared institutional and published protocols for thrombolytic treatment of occluded CVADs, in light of a systematic, evidence-based review of the literature on CVAD-related complications. Restoration of CVAD patency, when appropriate, represents a safe, effective, and costeffective alternative to device replacement and improves patient quality of life. The treatment algorithm presented in this article reflects the board's consensus recommendations for managing thrombotic CVAD occlusions in adult patients with cancer.

Jump to a section

    References

    Blaney, M., Shen, V., Kerner, J. A., Jacobs, B. R., Gray, S., Armfield, J., et al. (2006). Alteplase for the treatment of central venous catheter occlusion in children: Results of a prospective, openlabel, single-arm study (The Cathflo® Activase® Pediatric Study). Journal of Vascular and Interventional Radiology, 17(11, Pt.1), 1745-1751.
    Cancer Care Ontario. (2007). Cancer as a chronic disease: Implications for health care in Ontario. Retrieved July 2007, from http://www.cancercare.on.ca/AGM2007Presentation/AGMPresentation-MASTER-April25ts.ppt
    Deitcher, S. R., Fesen, M. R., Kiproff, P. M., Hill, P. A., Li, X., McCluskey, E. R., et al. (2002). Safety and efficacy of alteplase for restoring function in occluded central venous catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines Trial. Journal of Clinical Oncology, 20(1), 317-324.
    Dudrick, S. J. (2006). History of vascular access. Journal of Parenteral and Enteral Nutrition, 30(1, Suppl.), S47-S56.
    Fedan, J. S. (2003). Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) drugs. In C. R. Craig & R. E. Stitzel (Eds.), Modern pharmacology with clinical applications (6th ed., pp. 269-278). Lippincott Williams and Wilkins.
    Forauer, A. R., & Theoharis, C. (2003). Histologic changes in the human vein wall adjacent to indwelling central venous catheters. Journal of Vascular and Interventional Radiology, 14(9, Pt. 1), 1163-1168.
    Galloway, S., & Bodenham, A. (2004). Long-term central venous access. British Journal of Anaesthesia, 92(5), 722-734.
    Genentech, Inc. (2003). Cathflo® Activase® [Product insert]. South San Francisco, CA: Author.
    Grunfeld, E. (2006). Looking beyond survival: How are we looking at survivorship? Journal of Clinical Oncology, 24(32), 5166-5169.
    Hadaway, L. C. (2005). Reopen the pipeline for I. V. therapy. Nursing, 35(8), 54-61.
    Haire, W. D., Atkinson, J. B., Stephens, L. C., & Kotulak, G. D. (1994). Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thrombosis and Haemostasis, 72(4), 543-547.
    Haire, W. D., Deitcher, S. R., Mullane, K. M., Jaff, M. R., Firszt, C. M., Schulz, G. A., et al. (2004). Recombinant urokinase for restoration of patency in occluded central venous access devices: A doubleblind, placebo-controlled trial. Thrombosis and Haemostasis, 92(3), 575-582.
    Hamilton, H. (2006a). Complications associated with venous access devices: Part one. Nursing Standard, 20(26), 43-50.
    Hamilton, H. (2006b). Complications associated with venous access devices: Part two. Nursing Standard, 20(27), 59-65.
    Horne, M. K., III. (2004). Thrombolytics for occluded catheters. Critical Care Medicine, 32(10), 2146-2147.
    Hurtubise, M. R., Bottino, J. C., Lawson, M., & McCredie, K. B. (1980). Restoring patency of occluded central venous catheters. Archives of Surgery, 115(2), 212-213.
    Infusion Nurses Society. (2006). Policies and procedures for infusion nursing (3rd ed.). Norwood, MA: Infusion Nurses Society.
    Jacobs, B. R. (2003). Central venous catheter occlusion and thrombosis. Critical Care Clinics, 19(3), 489-514.
    Jacobs, B. R., Haygood, M., & Hingl, J. (2001). Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. Journal of Pediatrics, 139(4), 593-596.
    Journeycake, J. M., & Buchanan, G. R. (2006). Catheter-related deep venous thrombosis and other catheter complications in children with cancer. Journal of Clinical Oncology, 24(28), 4575-4580.
    Kerner, J. A., Jr., Garcia-Careaga, M. G., Fisher, A. A., & Poole, R. L. (2006). Treatment of catheter occlusion in pediatric patients. Journal of Parenteral and Enteral Nutrition, 30(1, Suppl.), S73-S81.
    Kokotis, K. (2005). Cost containment and infusion services. Journal of Infusion Nursing, 28(3, Suppl.), S22-S32.
    Liu, C. Y., Jain, V., Shields, A. F., & Heilbrun, L. K. (2004). Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. Journal of Vascular and Interventional Radiology, 15(1, Pt. 1), 39-44.
    Maki, D. G., Stolz, S. M., Wheeler, S., & Mermel, L. A. (1997). Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Annals of Internal Medicine, 127(4), 257-266.
    Middleton, G., & Ruzevick, B. (2004). Alteplase (Cathflo® Activase®). Clinical Journal of Oncology Nursing, 8(4), 417-418.
    Moll, S., Kenyon, P., Bertoli, L., De Maio, J., Homesley, H., & Deitcher, S. R. (2006). Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. Journal of Clinical Oncology, 24(19), 3056-3060.
    Moureau, N., Poole, S., Murdock, M. A., Gray, S. M., & Semba, C. P. (2002). Central venous catheters in home infusion care: Outcomes analysis in 50,470 patients. Journal of Vascular and Interventional Radiology, 13(10), 1009-1016.
    Ng, R., Li, X., Tu, T., & Semba, C. P. (2004). Alteplase for treatment of occluded peripherally inserted central catheters: Safety and efficacy in 240 patients. Journal of Vascular and Interventional Radiology, 15(1, Pt. 1), 45-49.
    Oncology Nursing Society. (2004). Access device guidelines (2nd ed.). Pittsburgh, PA: Author.
    Ottawa Hospital. (2006, July). Central venous access device (CVAD): Restoring patency for thrombotic occlusion. Nursing policy, procedure, protocol manual. Ottawa, Canada: Author.
    Prandoni, P., Piccioli, A., & Griolami, A. (1999). Cancer and venous thromboembolism: An overview. Haematologica, 84(5), 437-445.
    Ponec, D., Irwin, D., Haire, W. D., Hill, P. A., Li, X., & McCluskey, E. R. (2001). Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. Journal of Vascular and Interventional Radiology, 12(8), 951-955.
    Registered Nurses Association of Ontario. (2002). Toolkit: Implementation of clinical practice guidelines. Retrieved December 1, 2006, from http://www.rnao.org/Storage/12/668_BPG_Toolkit
    Registered Nurses Association of Ontario. (2004). Assessment and device selection for vascular access. Retrieved May 1, 2007, from http://www.rnao.org/Storage/11/531_BPG_assess_device_select_vascular.pdf
    Registered Nurses Association of Ontario. (2005). Care and maintenance to reduce vascular access complications. Toronto, Canada: Author.
    Shen, V., Li, X., Murdock, M., Resnansky, L., McCluskey, E. R., & Semba, C. P. (2003). Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. Journal of Pediatric Hematology/Oncology, 25(1), 38-45.
    Steiger, E. (2006). Dysfunction and thrombotic complications of vascular access devices. Journal of Parenteral and Enteral Nutrition, 30(1, Suppl.), S70-S72.
    Valji, K. (2000). Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. Journal of Vascular and Interventional Radiology, 11(4), 411-420.
    Wingerter, L. (2003). Vascular access device thrombosis. Clinical Journal of Oncology Nursing, 7(3), 345-348.